<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:23:08Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9836218" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9836218</identifier>
        <datestamp>2023-01-13</datestamp>
        <setSpec>ajrccm</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="letter">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Am J Respir Crit Care Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Am J Respir Crit Care Med</journal-id>
              <journal-id journal-id-type="publisher-id">ajrccm</journal-id>
              <journal-title-group>
                <journal-title>American Journal of Respiratory and Critical Care Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1073-449X</issn>
              <issn pub-type="epub">1535-4970</issn>
              <publisher>
                <publisher-name>American Thoracic Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9836218</article-id>
              <article-id pub-id-type="pmcid">PMC9836218</article-id>
              <article-id pub-id-type="pmc-uid">9836218</article-id>
              <article-id pub-id-type="pmid">35015969</article-id>
              <article-id pub-id-type="publisher-manuscript">202111-2655LE</article-id>
              <article-id pub-id-type="doi">10.1164/rccm.202111-2655LE</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Correspondence</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mok</surname>
                    <given-names>Chris Ka Pun</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="fn1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Chunke</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yiu</surname>
                    <given-names>Karen</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chan</surname>
                    <given-names>Tat-On</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lai</surname>
                    <given-names>Kiu Cheung</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ling</surname>
                    <given-names>Kwun Cheung</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sun</surname>
                    <given-names>Yuanxin</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4382-2445</contrib-id>
                  <name>
                    <surname>Hui</surname>
                    <given-names>David S.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="fn2" ref-type="author-notes">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cheng</surname>
                    <given-names>Samuel M. S.</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="fn1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Peiris</surname>
                    <given-names>Malik</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="fn2" ref-type="author-notes">
                    <sup>‡</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp">
                    <sup>§</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Li Ka Shing Institute of Health Sciences<break/>Hong Kong Special Administrative Region, People’s Republic of China</aff>
                <aff id="aff2"><label><sup>2</sup></label>The Chinese University of Hong Kong<break/>Hong Kong Special Administrative Region, People’s Republic of China</aff>
                <aff id="aff3"><label><sup>3</sup></label>The University of Hong Kong<break/>Hong Kong Special Administrative Region, People’s Republic of China</aff>
              </contrib-group>
              <author-notes>
                <fn id="fn1">
                  <label>*</label>
                  <p>These authors contributed equally to the manuscript.</p>
                </fn>
                <fn id="fn2">
                  <label>
                    <sup>‡</sup>
                  </label>
                  <p>These authors contributed equally as senior authors.</p>
                </fn>
                <corresp id="cor1"><label><sup>§</sup></label>Corresponding author (e-mail: <email xlink:href="mailto:malik@hku.hk">malik@hku.hk</email>).</corresp>
              </author-notes>
              <pub-date date-type="pub" publication-format="electronic">
                <day>11</day>
                <month>1</month>
                <year>2022</year>
              </pub-date>
              <pub-date date-type="collection" publication-format="electronic">
                <day>01</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>11</day>
                <month>1</month>
                <year>2022</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>205</volume>
              <issue>7</issue>
              <fpage>844</fpage>
              <lpage>847</lpage>
              <permissions>
                <copyright-statement>Copyright © 2022 by the American Thoracic Society</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This article is open access and distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution Non-Commercial No Derivatives License 4.0</ext-link>. For commercial usage and reprints, please e-mail Diane Gern (<email xlink:href="mailto:dgern@thoracic.org">dgern@thoracic.org</email>).</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="rccm.202111-2655LE.pdf"/>
              <related-object object-id="10.1164/rccm.202111-2655LE_discussion" object-id-type="doi" object-type="discussion" id="ro2655LE"/>
              <funding-group specific-use="FundRef">
                <award-group award-type="grant">
                  <funding-source country="US">
                    <institution>Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19)</institution>
                  </funding-source>
                  <award-id>COVID1903003</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="1"/>
                <ref-count count="10"/>
                <page-count count="4"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p content-type="flushleft"><italic>To the Editor</italic>:</p>
            <p content-type="flushleft">CoronaVac is one of the World Health Organization–approved inactivated virus vaccines, and over 750 million doses have been administered in more than 40 countries. Phase three randomized clinical trials (RCTs) of CoronaVac showed efficacies against symptomatic illness of 50.65%, 65.30%, and 83.50% in Brazil, Indonesia, and Turkey, respectively (<xref rid="bib1" ref-type="bibr">1</xref>). Since these efficacy studies assessed outcomes within a few months after vaccination, the impact of antibody waning on virus variants has not been assessed. Breakthrough infections, some leading to severe disease and death, have been reported in CoronaVac vaccinated adults and have raised concern (<xref rid="bib2" ref-type="bibr">2</xref>). Our recent observational study showed that the immunogenicity of CoronaVac is much lower compared with the BNT162b2 mRNA vaccine, and we estimated that waning immunity would lead to a loss of protection within a few months (<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>). A third vaccine dose was considered for CoronaVac vaccinated individuals. Here, we report the results of an RCT to compare the immunogenicity of using BNT162b2 and CoronaVac as the third dose for adults with low antibody response to two doses of CoronaVac.</p>
            <p>Some of the results of these studies have been previously reported in the form of a preprint (medRxiv; [accessed 2021 Nov 3]; <ext-link xlink:href="https://doi.org/10.1101/2021.11.02.21265843" ext-link-type="uri">https://doi.org/10.1101/2021.11.02.21265843</ext-link>).</p>
            <sec sec-type="methods" disp-level="2">
              <title>Methods</title>
              <p content-type="flushleft">Of the 360 participants who had received two doses of CoronaVac as part of our previous study (<xref rid="bib3" ref-type="bibr">3</xref>), 260 showed surrogate neutralization test (sVNT) results below 60% in their plasma specimens that were collected 1 month after the second dose. Eighty participants, aged 34–73 years, were randomly invited from the 260 participants and randomized to receive a third vaccine dose of either BNT162b2 or CoronaVac between August 18, 2021, and October 26, 2021. This clinical trial has been registered at ClinicalTrials.gov with identifier NCT04611243.</p>
              <p>The primary outcome was antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) measured by sVNTs, plaque reduction neutralization tests (PRNTs), and N-terminal domain (NTD) ELISA in plasma samples collected 1 month after the third dose of vaccination, which was performed according to our previous study (<xref rid="bib3" ref-type="bibr">3</xref>). The secondary outcome was the occurrence of adverse reactions within 7 days and 1 month after the third dose of vaccination. The standard deviation of the percentage of inhibition in the sVNT in the postvaccine plasma from our cohort for BNT1626 and CoronaVac was 3.45 and 16.72, respectively (<xref rid="bib3" ref-type="bibr">3</xref>). Therefore, a sample size of 40 patients in each group was estimated to have over 90% power to detect a difference of 10% in sVNT by using a two-sided, unpaired <italic>t</italic> test.</p>
            </sec>
            <sec sec-type="results" disp-level="2">
              <title>Results</title>
              <p content-type="flushleft">Additional details of the study design and the demographic information can be found at <ext-link xlink:href="https://www.mect.cuhk.edu.hk/paper/Supporting-Information.pdf" ext-link-type="uri">https://www.mect.cuhk.edu.hk/paper/Supporting-Information.pdf</ext-link>. The age and gender of the participants were not significantly different between the two groups (<xref rid="tbl1" ref-type="table">Table 1</xref>). Local and systemic adverse reactions were assessed and compared between the two groups (<xref rid="tbl1" ref-type="table">Table 1</xref>). More participants in the BNT162b2 (third dose) group reported pain (<italic>P</italic> &lt; 0.001) and swelling (<italic>P</italic> &lt; 0.05) at the injection site than those receiving CoronaVac as the third dose. Significantly more participants in the BNT162b2 (third dose) group complained of fatigue (<italic>P</italic> &lt; 0.01) and muscle pain (<italic>P</italic> &lt; 0.05) compared with the CoronaVac (third dose) group. However, none of these side effects were considered unacceptable by the participants.</p>
              <table-wrap position="float" id="tbl1">
                <label>
Table 1.
</label>
                <caption>
                  <p>Adverse Reactions after Receiving the Third Dose of Vaccination</p>
                </caption>
                <!--OASIS TABLE HERE-->
                <table frame="hsides" rules="groups">
                  <colgroup>
                    <col align="left"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                  </colgroup>
                  <thead>
                    <tr valign="bottom">
                      <th align="left" valign="bottom"> </th>
                      <th colspan="2" align="center" valign="bottom">After Second Dose<hr/></th>
                      <th align="center" valign="bottom"> </th>
                      <th colspan="2" align="center" valign="bottom">After Third Dose<hr/></th>
                      <th align="center" valign="bottom"> </th>
                    </tr>
                    <tr valign="bottom">
                      <th align="left" valign="bottom"> </th>
                      <th align="center" valign="bottom">C,C,B</th>
                      <th align="center" valign="bottom">C,C,C</th>
                      <th align="center" valign="bottom"><italic>P</italic> Value</th>
                      <th align="center" valign="bottom">C,C,B</th>
                      <th align="center" valign="bottom">C,C,C</th>
                      <th align="center" valign="bottom"><italic>P</italic> Value</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left">
                        <italic>n</italic>
                      </td>
                      <td align="center">40</td>
                      <td align="center">40</td>
                      <td align="center"> </td>
                      <td align="center">40</td>
                      <td align="center">40</td>
                      <td align="center"> </td>
                    </tr>
                    <tr>
                      <td align="left">Age (mean ± SD)</td>
                      <td align="center"> </td>
                      <td align="center"> </td>
                      <td align="center"> </td>
                      <td align="center">51.20 ± 8.79</td>
                      <td align="center">51.50 ± 8.83</td>
                      <td align="center">0.883<xref rid="TF2" ref-type="table-fn">*</xref></td>
                    </tr>
                    <tr>
                      <td align="left">Age (median, IQR)</td>
                      <td align="center"> </td>
                      <td align="center"> </td>
                      <td align="center"> </td>
                      <td align="center">51.50 (44.25–57)</td>
                      <td align="center">50.00 (45.25–57)</td>
                      <td align="center">0.969<xref rid="TF2" ref-type="table-fn">*</xref></td>
                    </tr>
                    <tr>
                      <td align="left">Male (female)</td>
                      <td align="center"> </td>
                      <td align="center"> </td>
                      <td align="center"> </td>
                      <td align="center">16 (24)</td>
                      <td align="center">12 (28)</td>
                      <td align="center">0.482<xref rid="TF2" ref-type="table-fn">*</xref></td>
                    </tr>
                    <tr>
                      <td align="left">Days between first and third dose</td>
                      <td align="center"> </td>
                      <td align="center"> </td>
                      <td align="center"> </td>
                      <td align="center">126.75</td>
                      <td align="center">128.75</td>
                      <td align="center">0.729<xref rid="TF2" ref-type="table-fn">*</xref></td>
                    </tr>
                    <tr>
                      <td align="left">Days between second and third dose</td>
                      <td align="center"> </td>
                      <td align="center"> </td>
                      <td align="center"> </td>
                      <td align="center">97.95</td>
                      <td align="center">99.35</td>
                      <td align="center">0.806<xref rid="TF2" ref-type="table-fn">*</xref></td>
                    </tr>
                    <tr>
                      <td colspan="7" align="left">Local reactions</td>
                    </tr>
                    <tr>
                      <td align="left"> Pain</td>
                      <td align="center">12</td>
                      <td align="center">13</td>
                      <td align="center">1.000</td>
                      <td align="center">34</td>
                      <td align="center">12</td>
                      <td align="center">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left"> Erythema</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">2</td>
                      <td align="center">0</td>
                      <td align="center">0.494</td>
                    </tr>
                    <tr>
                      <td align="left"> Pruritus</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">3</td>
                      <td align="center">1</td>
                      <td align="center">0.616</td>
                    </tr>
                    <tr>
                      <td align="left"> Swelling</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">14</td>
                      <td align="center">4</td>
                      <td align="center">0.014</td>
                    </tr>
                    <tr>
                      <td colspan="7" align="left">Systemic reactions</td>
                    </tr>
                    <tr>
                      <td align="left"> Fever<xref rid="TF3" ref-type="table-fn"><sup>†</sup></xref></td>
                      <td align="center">2</td>
                      <td align="center">2</td>
                      <td align="center">1.000</td>
                      <td align="center">7</td>
                      <td align="center">1</td>
                      <td align="center">0.057</td>
                    </tr>
                    <tr>
                      <td align="left"> Fatigue</td>
                      <td align="center">16</td>
                      <td align="center">14</td>
                      <td align="center">0.818</td>
                      <td align="center">24</td>
                      <td align="center">10</td>
                      <td align="center">0.003</td>
                    </tr>
                    <tr>
                      <td align="left"> Diarrhea</td>
                      <td align="center">2</td>
                      <td align="center">3</td>
                      <td align="center">1.000</td>
                      <td align="center">1</td>
                      <td align="center">0</td>
                      <td align="center">1</td>
                    </tr>
                    <tr>
                      <td align="left"> Muscle pain</td>
                      <td align="center">8</td>
                      <td align="center">4</td>
                      <td align="center">0.348</td>
                      <td align="center">13</td>
                      <td align="center">4</td>
                      <td align="center">0.027</td>
                    </tr>
                    <tr>
                      <td align="left"> Nausea</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">2</td>
                      <td align="center">0</td>
                      <td align="center">0.494</td>
                    </tr>
                    <tr>
                      <td align="left"> Headache</td>
                      <td align="center">5</td>
                      <td align="center">5</td>
                      <td align="center">1.000</td>
                      <td align="center">10</td>
                      <td align="center">3</td>
                      <td align="center">0.067</td>
                    </tr>
                    <tr>
                      <td align="left"> Cough</td>
                      <td align="center">2</td>
                      <td align="center">0</td>
                      <td align="center">0.494</td>
                      <td align="center">2</td>
                      <td align="center">2</td>
                      <td align="center">1</td>
                    </tr>
                    <tr>
                      <td align="left"> Anorexia</td>
                      <td align="center">0</td>
                      <td align="center">1</td>
                      <td align="center">1.000</td>
                      <td align="center">4</td>
                      <td align="center">1</td>
                      <td align="center">0.359</td>
                    </tr>
                    <tr>
                      <td align="left"> Hypoesthesia</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">4</td>
                      <td align="center">0</td>
                      <td align="center">0.116</td>
                    </tr>
                    <tr>
                      <td align="left"> Dizziness</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">6</td>
                      <td align="center">2</td>
                      <td align="center">0.264</td>
                    </tr>
                    <tr>
                      <td align="left"> Abdominal distention</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">1</td>
                      <td align="center">0</td>
                      <td align="center">1</td>
                    </tr>
                    <tr>
                      <td align="left"> Peripheral edema</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">1</td>
                      <td align="center">0</td>
                      <td align="center">1</td>
                    </tr>
                    <tr>
                      <td align="left"> Abdominal pain</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">1</td>
                      <td align="center">0</td>
                      <td align="center">1</td>
                    </tr>
                    <tr>
                      <td align="left"> Vomiting</td>
                      <td align="center">0</td>
                      <td align="center">0</td>
                      <td align="center">N.A.</td>
                      <td align="center">0</td>
                      <td align="center">0</td>
                      <td align="center">N.A.</td>
                    </tr>
                    <tr>
                      <td align="left"> Drowsiness</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">11</td>
                      <td align="center">8</td>
                      <td align="center">0.601</td>
                    </tr>
                    <tr>
                      <td align="left"> Joint pains</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">6</td>
                      <td align="center">3</td>
                      <td align="center">0.482</td>
                    </tr>
                    <tr>
                      <td align="left"> Rash</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">2</td>
                      <td align="center">0</td>
                      <td align="center">0.494</td>
                    </tr>
                    <tr>
                      <td align="left"> Palpitation</td>
                      <td align="center">—</td>
                      <td align="center">—</td>
                      <td align="center">N.A.</td>
                      <td align="center">5</td>
                      <td align="center">2</td>
                      <td align="center">0.432</td>
                    </tr>
                    <tr>
                      <td align="left"> Claimed no adverse effect</td>
                      <td align="center">15</td>
                      <td align="center">14</td>
                      <td align="center">1.000</td>
                      <td align="center">8</td>
                      <td align="center">16</td>
                      <td align="center">0.087</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="TF1">
                    <p><italic>Definition of abbreviations</italic>: — = did not include in the questionnaire; B = BNT162b2; C = CoronaVac; C,C,B and C,C,C = vaccines used for the first, second, and third dose of vaccination; IQR = interquartile range; N.A. = not available.</p>
                  </fn>
                  <fn id="TF2">
                    <label>*</label>
                    <p>Analyzed by the Mann-Whitney <italic>U</italic> test. All other comparisons were analyzed by Fisher's exact test.</p>
                  </fn>
                  <fn id="TF3">
                    <label>
                      <sup>†</sup>
                    </label>
                    <p>Oral temperature above 37.5°C was considered a fever.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>We used sVNT (<xref rid="bib5" ref-type="bibr">5</xref>), PRNT, and NTD ELISA to quantify levels of SARS-CoV-2–specific antibody from the plasma samples collected before vaccination, at 1 month after the second dose, and before and at 1 month after the third dose of vaccination. Antibody levels from vaccinees in the two groups were negative in sVNT before any vaccination, and the sVNT showed comparable results in the two groups at 1 month after the second dose, as expected. One month after the third dose of vaccination, the mean percentage of inhibition in the sVNT in the plasma for the BNT1626 and CoronaVac groups was 96.83% and 57.75%, respectively (<italic>P</italic> &lt; 0.0001) (<xref rid="fig1" ref-type="fig">Figure 1A</xref>). The 90% plaque reduction neutralization (PRNT<sub>90</sub>) geometric mean titers in the BNT162b2 and CoronaVac groups were 207.49 and 16.53, respectively (<xref rid="fig1" ref-type="fig">Figure 1B</xref>); and PRNT<sub>50</sub> geometric mean titers were 303.79 and 56.67, respectively. We had previously estimated that 50% of individuals would be protected from infection at a PRNT<sub>90</sub> titer of ⩾1:8.8 (<xref rid="bib3" ref-type="bibr">3</xref>). Thus, all BNT162b2 and 35 (87.5%) of 40 CoronaVac-boosted individuals had protective levels of antibody at 1-month after a booster dose of vaccine. The level of NTD IgG antibodies was significantly higher in BNT162b2 recipients (<xref rid="fig1" ref-type="fig">Figure 1C</xref>).</p>
              <fig position="float" id="fig1">
                <label>
Figure 1.
</label>
                <caption>
                  <p>Antibody responses of individuals before and after the third dose of either BNT162b2 or CoronaVac. The levels of antibodies after the third dose of either BNT162b2 (<italic>n</italic> = 40) or CoronaVac (<italic>n</italic> = 40) were detected from the plasma collected from vaccinated adult individuals who had received two doses of CoronaVac. (<italic>A</italic>) Surrogate virus neutralization test (sVNT). (<italic>B</italic>) A 90% plaque reduction neutralization (PRNT<sub>90</sub>). The titers have been jittered to avoid overlap. The dotted line denotes the threshold for protection of 50% of individuals from infection (<xref rid="bib3" ref-type="bibr">3</xref>). (<italic>C</italic>) N-terminal domain (NTD)-specific immunoglobulin G (IgG) antibodies. (<italic>D</italic>) The percentage of inhibition against the wild-type, β, γ, and δ variants was compared between the two groups at 1 month after the third dose of vaccination. Comparison between groups was analyzed by the nonparametric Mann-Whitney <italic>U</italic> test. ****<italic>P</italic> &lt; 0.0001. B = BNT162b2; C = CoronaVac; C,C,B and C,C,C = vaccines used for the first, second, and third dose of vaccination; WT = wild type.</p>
                </caption>
                <graphic xlink:href="rccm.202111-2655LEf1" position="float"/>
              </fig>
              <p>We tested the sVNT activity in the plasma samples against different variants of concern. Percent inhibition of sVNT against the β, γ, and δ variants in the BNT162b2 group were 92.29%, 92.51%, and 95.33%, respectively, which are significantly higher than the CoronaVac group (β: 38.79%, <italic>P</italic> &lt; 0.0001; γ: 32.22%, <italic>P</italic> &lt; 0.0001; δ: 48.87%, <italic>P</italic> &lt; 0.0001) (<xref rid="fig1" ref-type="fig">Figure 1D</xref>).</p>
            </sec>
            <sec sec-type="discussion" disp-level="2">
              <title>Discussion</title>
              <p content-type="flushleft">Reinfection of SARS-CoV-2 in vaccinated individuals is now a public health concern, and breakthrough cases, some severe, are being reported by different countries (<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>).</p>
              <p>Lower immunogenicity of CoronaVac vaccines was previously reported by us and others (<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib8" ref-type="bibr">8</xref>). Two recent studies showed data on using BNT1626 or AZD1222 as the third dose for adults who had received two doses of CoronaVac (<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>). However, neither study was randomized; they lacked longitudinal data to compare antibody levels before and after receiving the boosting dose, and adverse reactions were not evaluated. This is the first RCT to compare the immunogenicity and adverse effects of using BNT162b2 and CoronaVac as the third dose for vaccination in CoronaVac-immunized individuals, and we showed markedly higher antibody responses in those boosted by the BNT162b2 vaccine.</p>
              <p>There were some limitations in our study. The sample size in our study was adequate for assessing immunogenicity but too small to fully assess rare adverse effects. Our study cohort only focused on those who had a poor response to the CoronaVac vaccine. Elderly and immunosuppressed patients, who are known to respond poorly to the coronavirus disease (COVID-19) vaccine, need to be investigated in future studies. T-cell responses were not assessed in this study.</p>
              <p>In conclusion, our RCT showed that both CoronaVac and BNT162b2 vaccines boosted antibody responses in CoronaVac-immunized individuals, but BNT162B2 was markedly superior in immunogenicity. BNT162b2 not only elicited a higher level of SARS-CoV-2-specific antibodies but also led to higher levels of cross-neutralizing antibody levels to different variants of concern
. The adverse reactions were mild and short lived.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="supported-by">
                <p>Supported by grants from the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong Special Administration Region (COVID1903003; COVID190126) (C.K.P.M., M.P., and D.S.H.), Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (C.K.P.M.), a National Research Foundation of Korea (NRF) grant funded through the Korea government (NRF-2018M3A9H4055203) (C.K.P.M.), NIH (contract no. U01-Grant AI151810) (M.P.), National Natural Science Foundation of China/Research Grants Council (RGC) Joint Research Scheme (N_HKU737/18) (C.K.P.M. and M.P.), and RGC theme-based research schemes (T11-712/19-N and T11-705/21-N) (D.S.H. and M.P.).</p>
              </fn>
              <fn>
                <p>Author Contributions: C.K.P.M.: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, supervision, visualization, writing (original draft), and writing (review and editing); S.M.S.C.: data curation, investigation, and methodology; C.C.: data curation and investigation; K.Y.: project administration; T.-O.C.: formal analysis; K. C. Lai: investigation; K. C. Ling: project administration; Y.S.: investigation; M.P.: conceptualization, formal analysis, funding acquisition, supervision, writing—original draft, and writing–—review and editing; D.S.H.: conceptualization, formal analysis, funding acquisition, supervision, writing (original draft), and writing (review and editing); all authors critically reviewed and commented on the manuscript.</p>
              </fn>
              <fn>
                <p>Originally Published in Press as DOI: <ext-link xlink:href="https://doi.org/10.1164/rccm.202111-2655LE" ext-link-type="uri">10.1164/rccm.202111-2655LE</ext-link> on January 11, 2022</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><underline><bold><ext-link xlink:href="http://www.atsjournals.org/doi/suppl/10.1164/rccm.202111-2655LE/suppl_file/disclosures.pdf" ext-link-type="uri">Author disclosures</ext-link></bold></underline> are available with the text of this letter at <ext-link xlink:href="http://www.atsjournals.org" ext-link-type="uri">www.atsjournals.org</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bib1">
                <label>1.</label>
                <mixed-citation publication-type="other">
                  <collab>World Health Organization</collab>
                  <year>2021</year>
                  <ext-link xlink:href="https://extranet.who.int/pqweb/sites/default/files/documents/SINOVAC_TAG_PEG_REPORT_EUL-Final28june2021.pdf" ext-link-type="uri">https://extranet.who.int/pqweb/sites/default/files/documents/SINOVAC_TAG_PEG_REPORT_EUL-Final28june2021.pdf</ext-link>
                </mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2.</label>
                <mixed-citation publication-type="other">
                  <article-title>Hundreds of vaccinated Indonesian health workers infected</article-title>
                  <source>
                    <italic>Bangkok Post</italic>
                  </source>
                  <year>2021</year>
                  <ext-link xlink:href="https://www.bangkokpost.com/world/2133987/hundreds-of-vaccinated-indonesian-health-workers-infected" ext-link-type="uri">https://www.bangkokpost.com/world/2133987/hundreds-of-vaccinated-indonesian-health-workers-infected</ext-link>
                </mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mok</surname>
                      <given-names>CKP</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Cheng</surname>
                      <given-names>SMS</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Kwok</surname>
                      <given-names>KO</given-names>
                    </name>
                    <name>
                      <surname>Yiu</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong</article-title>
                  <source>
                    <italic>Respirology</italic>
                  </source>
                </mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Khoury</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Cromer</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Reynaldi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Schlub</surname>
                      <given-names>TE</given-names>
                    </name>
                    <name>
                      <surname>Wheatley</surname>
                      <given-names>AK</given-names>
                    </name>
                    <name>
                      <surname>Juno</surname>
                      <given-names>JA</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection</article-title>
                  <source>
                    <italic>Nat Med</italic>
                  </source>
                  <year>2021</year>
                  <volume>27</volume>
                  <fpage>1205</fpage>
                  <lpage>1211</lpage>
                  <pub-id pub-id-type="pmid">34002089</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib5">
                <label>5.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lau</surname>
                      <given-names>EHY</given-names>
                    </name>
                    <name>
                      <surname>Hui</surname>
                      <given-names>DSC</given-names>
                    </name>
                    <name>
                      <surname>Tsang</surname>
                      <given-names>OTY</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Kwan</surname>
                      <given-names>MYK</given-names>
                    </name>
                    <name>
                      <surname>Chiu</surname>
                      <given-names>SS</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection</article-title>
                  <source>
                    <italic>EClinicalMedicine</italic>
                  </source>
                  <year>2021</year>
                  <volume>41</volume>
                  <fpage>101174</fpage>
                  <pub-id pub-id-type="pmid">34746725</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib6">
                <label>6.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pietsch</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Hundreds of Thais inoculated with Sinovac are infected as cases spike in Southeast Asia</article-title>
                  <source>
                    <italic>The Washington Post</italic>
                  </source>
                  <year>2021</year>
                  <ext-link xlink:href="https://www.washingtonpost.com/world/2021/07/12/coronaviruslatest-updates" ext-link-type="uri">https://www.washingtonpost.com/world/2021/07/12/coronaviruslatest-updates</ext-link>
                </mixed-citation>
              </ref>
              <ref id="bib7">
                <label>7.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chau</surname>
                      <given-names>NVV</given-names>
                    </name>
                    <name>
                      <surname>Ngoc</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Nguyet</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Quang</surname>
                      <given-names>VM</given-names>
                    </name>
                    <name>
                      <surname>Ny</surname>
                      <given-names>NTH</given-names>
                    </name>
                    <name>
                      <surname>Khoa</surname>
                      <given-names>DB</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>An observational study of breakthrough SARS-CoV-2 delta variant infections among vaccinated healthcare workers in Vietnam</article-title>
                  <source>
                    <italic>EClinicalMedicine</italic>
                  </source>
                  <year>2021</year>
                  <volume>41</volume>
                  <fpage>101143</fpage>
                  <pub-id pub-id-type="pmid">34608454</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib8">
                <label>8.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lim</surname>
                      <given-names>WW</given-names>
                    </name>
                    <name>
                      <surname>Mak</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Leung</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Cowling</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Peiris</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19</article-title>
                  <source>
                    <italic>Lancet Microbe</italic>
                  </source>
                  <year>2021</year>
                  <volume>2</volume>
                  <fpage>e423</fpage>
                  <pub-id pub-id-type="pmid">34308395</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib9">
                <label>9.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yorsaenga</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Suntronwonga</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Phowatthanasathiana</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Assawakosria</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kanokudoma</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Thongmeea</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal>
                      <italic>et al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults</article-title>
                  <source>
                    <italic>Vaccine</italic>
                  </source>
                  <year>2022</year>
                  <volume>40</volume>
                  <fpage>524</fpage>
                  <lpage>530</lpage>
                  <pub-id pub-id-type="pmid">34893344</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib10">
                <label>10.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Keskin</surname>
                      <given-names>AU</given-names>
                    </name>
                    <name>
                      <surname>Bolukcu</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ciragil</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Topkaya</surname>
                      <given-names>AE</given-names>
                    </name>
                  </person-group>
                  <article-title>SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen</article-title>
                  <source>
                    <italic>J Med Virol</italic>
                  </source>
                  <year>2022</year>
                  <volume>94</volume>
                  <fpage>39</fpage>
                  <lpage>41</lpage>
                  <pub-id pub-id-type="pmid">34536028</pub-id>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
